Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ to test checkpoint inhibitors with Immunocore's TCR candidate

This article was originally published in Scrip

Executive Summary

AstraZeneca, via its MedImmune unit, has entered a second collaboration with promising UK biotech Immunocore in the area of immune-oncology. Under the new agreement, Immunocore will conduct a Phase Ib/II trial combining AstraZeneca's investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, Immunocore's lead T-cell receptor based therapeutic candidate, for the potential treatment of metastatic melanoma. MedImmune will have first right of negotiation for the future commercial development of these combinations for tumours expressing gp100. The companies have a pre-existing agreement, announced in January 2014, to develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028439

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel